Methoxsalen loaded chitosan coated microemulsion for effective treatment of psoriasis.

Behera, Jitendra K.; Keservani, Raj K.; Yadav, Arvind Kumar; Tripathi, Meenendra; Chadoker, Anoop

doi:10.5138/ijdd.2010.0975.0215.02025

Cited by 21 publications

(13 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is worth noticing that after SLN TRC 2% and TRC 4% application, the % of the drug accumulated in each skin layer was significantly greater than that found after SLN TRC 0% application. The ability of different lipidic nanocarriers to enhance 8-MOP skin delivery has been previously reported in the literature [ 6 , 7 , 8 , 9 , 10 , 11 , 14 , 25 , 26 , 27 , 28 ]. For instance, in our group’s previous study, we incorporated 8-MOP into vesicular carriers (liposomes and niosomes) positively or negatively charged and we investigated their effect on 8-MOP diffusion through the skin and on its distribution within the skin layers.…”

Section: Resultsmentioning

confidence: 99%

Transcutol® P Containing SLNs for Improving 8-Methoxypsoralen Skin Delivery

et al. 2020

View full text Add to dashboard Cite

Topical psoralens plus ultraviolet A radiation (PUVA) therapy consists in the topical application of 8-methoxypsoralen (8-MOP) followed by the skin irradiation with ultraviolet A radiation. The employment of classical 8-MOP vehicles in topical PUVA therapy is associated with poor skin deposition and weak skin permeability of psoralens, thus requiring frequent drug administration. The aim of the present work was to formulate solid lipid nanoparticles (SLNs) able to increase the skin permeation of 8-MOP. For this purpose, the penetration enhancer Transcutol® P (TRC) was added to the SLN formulation. SLNs were characterized with respect to size, polydispersity index, zeta potential, entrapment efficiency, morphology, stability, and biocompatibility. Finally, 8-MOP skin diffusion and distribution within the skin layers was investigated using Franz cells and newborn pig skin. Freshly prepared nanoparticles showed spherical shape, mean diameters ranging between 120 and 133 nm, a fairly narrow size distribution, highly negative ζ potential values, and high entrapment efficiency. Empty and loaded formulations were almost stable over 30 days. In vitro penetration and permeation studies demonstrated a greater 8-MOP accumulation in each skin layer after SLN TRC 2% and TRC 4% application than that after SLN TRC 0% application. Finally, the results of experiments on 3T3 fibroblasts showed that the incorporation of TRC into SLNs could enhance the cellular uptake of nanoparticles, but it did not increase their cytotoxicity.

show abstract

Section: Resultsmentioning

confidence: 99%

Transcutol® P Containing SLNs for Improving 8-Methoxypsoralen Skin Delivery

et al. 2020

View full text Add to dashboard Cite

show abstract

“…This was centrifuged at 3000×g for 15 min and the supernatant was collected. Equal volumes of the optimized itraconazole loaded ME formulation and chitosan solution were mixed to form the chitosan-coated drug loaded ME formulation (CS-TMI) (Behera et al 2010).…”

Section: Preparation Of Chitosan-coated Microemulsionmentioning

confidence: 99%

“…The pH of the formulations was determined using a digital pH meter (Systronics digital pH meter 335, India), at 25 ± 1°C. A total of 2.5 g of the CS-TMI formulation was dispersed in 25 ml of distilled water and the pH of the dispersed solution was measured (Behera et al 2010).…”

Section: Ph Measurementmentioning

confidence: 99%

In Vivo Testing and Extended Drug Release of Chitosan-Coated Itraconazole Loaded Microemulsion Using Volatile Oil Thymus vulgaris

Ebenazer

Franklyne

Tiwari

et al. 2020

Rev. Bras. Farmacogn.

View full text Add to dashboard Cite

Microemulsions are potent drug delivery vehicles as they solubilize water insoluble drugs with poor bioavailability. The main aim of this study was to develop, optimize, and assess a thyme oil microemulsion with inherent antifungal activity for transdermal drug delivery of itraconazole. The optimized thyme oil microemulsion contains thyme oil, Cremophor EL, and water at 5:25:70% v/v respectively. The drug loaded microemulsion was mixed in equal proportion with chitosan for cutaneous application. The droplet size, zeta potential, FTIR spectra, and antifungal activity of the drug free microemulsion and drug loaded microemulsions with/without chitosan were characterized. The ex vivo drug permeation of drug loaded microemulsions with/without chitosan was compared with that of the bulk drug, using the Franz diffusion apparatus with the excised skin from Wistar rats. The droplet size of the drug free microemulsion and drug loaded microemulsions with/without chitosan were 25.53 ± 3.84 nm, 168.6 ± 13.33 nm, and 35.13 ± 0.41 nm respectively, with a polydispersity index between 0.436 and 0.658. The FTIR spectra demonstrated no changes in the structure of the drug in the drug loaded microemulsions with/without chitosan. The in vitro antifungal studies against Candida albicans exhibited similar zones of inhibition between bulk drug and drug loaded microemulsion, while the minimum inhibitory concentration showed a 2-fold decrease with drug loaded microemulsions with/without chitosan compared with the bulk drug. SEM confirmed substantial morphological changes in C. albicans cell membrane. The drug loaded microemulsion with chitosan revealed a slow and sustained release of itraconazole in phosphate buffered saline (pH 7.4) proving it to be an efficient, stable, and sustained topical delivery vehicle.

show abstract

“…The use of ME a vehicle for methosalen (drug name for 8-MOP) in the treatment of psoriasis was the subject of a study by Behera and colleagues (2010), [128] the authors compared chitosan coated ME with conventional ME, both containing methoxsalen. Assays were performed on cutaneous permeation in human cadaver, skin, and the results showed that the new system of chitosan-coated ME, with methoxsalen was promising for treating psoriasis, providing controlled release, promoting at skin, and better application of the product on the skin, relative to the ME, resulting in better adherence to the treatment by the patient [128].…”

Section: Liquid Crystal Systemsmentioning

confidence: 99%

Nanotechnology-Based Drug Delivery Systems for Treatment of Hyperproliferative Skin Diseases - A Review

Santos¹,

Oyafuso²,

Kiill³

et al. 2013

Current Nanoscience

View full text Add to dashboard Cite

The chronic hyperproliferative diseases (CHD) include cancer, precancerous lesions and diseases of unknown etiology such as psoriasis. Various drugs have been used in the treatment of CHD, such as antiproliferative and corticosteroids in general. However, some drugs have properties that limit their effectiveness, such as low solubility in water and low penetration of the skin. Thus, the control of drug release in the skin may improve efficacy and reduce side effects of many drugs used in hyperproliferative diseases. The purpose of this study was to make a systematic review of nanotechnology-based drug delivery systems used against hyperproliferative skin diseases.

show abstract

Methoxsalen loaded chitosan coated microemulsion for effective treatment of psoriasis.

Cited by 21 publications

References 5 publications

Transcutol® P Containing SLNs for Improving 8-Methoxypsoralen Skin Delivery

Transcutol® P Containing SLNs for Improving 8-Methoxypsoralen Skin Delivery

In Vivo Testing and Extended Drug Release of Chitosan-Coated Itraconazole Loaded Microemulsion Using Volatile Oil Thymus vulgaris

Nanotechnology-Based Drug Delivery Systems for Treatment of Hyperproliferative Skin Diseases - A Review

Contact Info

Product

Resources

About